CSF2 and neuroblastoma: Compared with standard therapy (six cycles of 13-cis-retinoic acid), dinutuximab significantly improved clinical outcomes in combination with alternating granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-2 after standard therapy in patients with high-risk neuroblastoma [754].